Research Paper Volume 16, Issue 12 pp 10216—10238

Figure 5. EGR1 positively regulates the expression of NR4A3. (A–C) NPCs were transfected with 25 nM Control siRNA or EGR1 siRNA-1 for 24 hours and then treated with 50 μM TBHP for 24 hours before protein or mRNA extraction. The mRNA and protein expression levels of NR4A3 were determined by qRT-PCR and Western blotting. (D–F) NPCs were transfected with 5 μg of the EGR1 expression plasmid or its control vector for 24 hours and then treated with 50 μM TBHP for 24 hours before protein or mRNA extraction. The mRNA and protein expression of NR4A3 was determined by qRT-PCR and Western blotting. (G) The expression of NR4A3 in SDD and MDD patients was examined by IHC staining. (H) The protein expression of NR4A3 in SDD and MDD was examined by Western blotting. (I) Quantitative analysis of NR4A3 protein level in SDD and MDD. (J) The mRNA expression of NR4A3 in TBHP-treated NPCs was examined by qRT-PCR. (K) NPCs were treated with 0, 25, 50, or 100 μM TBHP for 24 h, after which the protein was extracted, and the NR4A3 expression level was determined by Western blotting. (L) Quantitative analysis of the NR4A3 protein level. ^*p < 0.05, ^**p < 0.01, ^***p < 0.001, ^****p < 0.0001.